Identification of Notch Signaling Pathway Gene Mutations as a Prognostic Biomarker for Bladder Cancer

<b>Purpose:</b> The authors aimed to identify Notch signaling pathway gene mutations as a prognostic biomarker for bladder cancer. <b>Methods:</b> First, critical Notch signaling pathway genes were screened using The Cancer Genome Atlas and validation sets. Second, immune infiltration, protein–protein interaction network, Kyoto Encyclopedia of Genes and Genomes and Gene Set Enrichment Analysis analyses were performed. Finally, potential immunotherapy drug targets were screened using T-cell receptors, B-cell receptors and CERES scores for bladder cancer. <b>Results:</b> The <i>NOTCH7</i> gene was identified, with a significant difference in immune infiltration level between mutant and wild type in bladder cancer, mainly related to T cells. NOTCH7 was an immunotherapy prognostic factor, and IRF1 and B2M were the potential drug targets for <i>NOTCH7</i> mutation in bladder cancer. <b>Conclusion:</b><i>NOTCH7</i> gene mutation can be used as an immunotherapy biomarker for bladder cancer. Studies have shown that 43% of bladder cancer patients harbor somatic mutations in genes associated with the Notch signaling pathway. However, it is not clear whether these mutations impact the efficacy of immunotherapy in bladder cancer patients. In the present study, the authors aimed to elucidate whether Notch signaling pathway gene mutations are effective biomarkers for predicting immunotherapy response and prognosis in patients with bladder cancer. Results of the present study suggested that seven genes – <i>CNTN6</i>, <i>CREBBP</i>, <i>EP300</i>, <i>NCOR1</i>, <i>NCOR2</i>, <i>NOTCH2</i> and <i>SPEN</i> – involved in the Notch signaling pathway can be used to predict the response of patients to immunotherapy. In addition, IRF1 and B2M can act as combination drug targets with these seven genes.